Cargando…
Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia
The prostate specific antigen (PSA) test is widely used for early diagnosis of prostate cancer (PCa). However, its limited sensitivity has led to over-diagnosis and over-treatment of PCa. Glycosylation alteration is a common phenomenon in cancer development. Different PSA glycan subforms have been p...
Autores principales: | Jia, Gaozhen, Dong, Zhenyang, Sun, Chenxia, Wen, Fuping, Wang, Haifeng, Guo, Huaizu, Gao, Xu, Xu, Chuanliang, Yang, Chenghua, Sun, Yinghao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652757/ https://www.ncbi.nlm.nih.gov/pubmed/29100363 http://dx.doi.org/10.18632/oncotarget.20299 |
Ejemplares similares
-
The Significance of PSA/IGF-1 Ratio in Differentiating Benign Prostate Hyperplasia from Prostate Cancer
por: Koliakos, G., et al.
Publicado: (2000) -
Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
por: Xu, Bei, et al.
Publicado: (2021) -
Three-dimensional printing technique assisted cognitive fusion in targeted prostate biopsy
por: Wang, Yan, et al.
Publicado: (2015) -
Benign Prostatic Hyperplasia
Publicado: (2015) -
Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity
por: Stephan, Carsten, et al.
Publicado: (2008)